| abstract |
PURPOSE: To obtain the titled inhibitor useful for the therapeutic treatment of complications of diabetes, e.g. corneal dysraphism, cataract, neuropathy, retinopathy and renal disorder, especially cataract and neuropathy, by using a specific quinazoline derivative as an active component. n CONSTITUTION: The objective agent contains, as an active component, a quinazoline derivative of formula I [R 1 is H, halogen or lower alkoxy; R 2 is dihalophenyl(lower)alkyl; Z is lower alkylene], e.g. 2-[3-(3,4-dichlorobenzyl)-1,2,3,4- tetrahydro-2,4-dioxoquinazolin-1-yl]acetic acid,or its pharmacologically allowable salt. The compound of formula I can be produced by reacting a compound of formula II or its salt with a compound of formula III [R 3 is (protected) carboxy; X is eliminable group] or its salt in a solvent in the presence of an organic or inorganic base and hydrolyzing the reaction product. It is administered at a rate of 0.1W100mg of the active component per 1kg of body weight per dose. n COPYRIGHT: (C)1989,JPO&Japio |